Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
暂无分享,去创建一个
D. Carbone | D. Spigel | G. Oxnard | A. Schrock | R. Huang | K. Tolba | R. Graf | J. Sands | Gerald Li | K. Murugesan | J. Ross | Liangliang Zhang | Richard S. P. Huang